Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer.

Maternal embryonic leucine-zipper kinase (MELK) regulates cell cycle progression and is highly expressed in many cancers. The molecular mechanism of MELK dysregulation has not been determined in aggressive forms of breast cancer, such as triple negative breast cancer (TNBC). To evaluate molecular ma...

Full description

Bibliographic Details
Main Authors: Ashley A Hardeman, Yoo Jane Han, Tatyana A Grushko, Jeffrey Mueller, Maria J Gomez, Yonglan Zheng, Olufunmilayo I Olopade
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0268693
_version_ 1811295124611661824
author Ashley A Hardeman
Yoo Jane Han
Tatyana A Grushko
Jeffrey Mueller
Maria J Gomez
Yonglan Zheng
Olufunmilayo I Olopade
author_facet Ashley A Hardeman
Yoo Jane Han
Tatyana A Grushko
Jeffrey Mueller
Maria J Gomez
Yonglan Zheng
Olufunmilayo I Olopade
author_sort Ashley A Hardeman
collection DOAJ
description Maternal embryonic leucine-zipper kinase (MELK) regulates cell cycle progression and is highly expressed in many cancers. The molecular mechanism of MELK dysregulation has not been determined in aggressive forms of breast cancer, such as triple negative breast cancer (TNBC). To evaluate molecular markers of MELK aberrations in aggressive breast cancer, we assessed MELK gene amplification and expression in breast tumors. MELK mRNA expression is highly up-regulated in basal-like breast cancer (BLBC), the major molecular subtype of TNBC, compared to luminal or other subtypes of breast tumors. MELK copy number (CN) gains are significantly associated with BLBC, whereas no significant association of CpG site methylation or histone modifications with breast cancer subtypes was observed. Accordingly, the CN gains appear to contribute to an increase in MELK expression, with a significant correlation between mRNA expression and CN in breast tumors and cell lines. Furthermore, immunohistochemistry (IHC) assays revealed that both nuclear and cytoplasmic staining scores of MELK were significantly higher in invasive ductal carcinoma (IDC) tumors compared to ductal carcinoma in situ (DCIS) and normal breast tissues. Our data showed that upregulation of MELK in BLBC may be in part driven by CN gains, rather than epigenetic modifications, indicating a potential for overexpression and CN gains of MELK to be developed as a diagnostic and prognostic marker to identify patients who have more aggressive breast cancer.
first_indexed 2024-04-13T05:27:53Z
format Article
id doaj.art-b7d9e314a3ee46559e693fba6ad190a7
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-04-13T05:27:53Z
publishDate 2022-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-b7d9e314a3ee46559e693fba6ad190a72022-12-22T03:00:32ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01176e026869310.1371/journal.pone.0268693Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer.Ashley A HardemanYoo Jane HanTatyana A GrushkoJeffrey MuellerMaria J GomezYonglan ZhengOlufunmilayo I OlopadeMaternal embryonic leucine-zipper kinase (MELK) regulates cell cycle progression and is highly expressed in many cancers. The molecular mechanism of MELK dysregulation has not been determined in aggressive forms of breast cancer, such as triple negative breast cancer (TNBC). To evaluate molecular markers of MELK aberrations in aggressive breast cancer, we assessed MELK gene amplification and expression in breast tumors. MELK mRNA expression is highly up-regulated in basal-like breast cancer (BLBC), the major molecular subtype of TNBC, compared to luminal or other subtypes of breast tumors. MELK copy number (CN) gains are significantly associated with BLBC, whereas no significant association of CpG site methylation or histone modifications with breast cancer subtypes was observed. Accordingly, the CN gains appear to contribute to an increase in MELK expression, with a significant correlation between mRNA expression and CN in breast tumors and cell lines. Furthermore, immunohistochemistry (IHC) assays revealed that both nuclear and cytoplasmic staining scores of MELK were significantly higher in invasive ductal carcinoma (IDC) tumors compared to ductal carcinoma in situ (DCIS) and normal breast tissues. Our data showed that upregulation of MELK in BLBC may be in part driven by CN gains, rather than epigenetic modifications, indicating a potential for overexpression and CN gains of MELK to be developed as a diagnostic and prognostic marker to identify patients who have more aggressive breast cancer.https://doi.org/10.1371/journal.pone.0268693
spellingShingle Ashley A Hardeman
Yoo Jane Han
Tatyana A Grushko
Jeffrey Mueller
Maria J Gomez
Yonglan Zheng
Olufunmilayo I Olopade
Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer.
PLoS ONE
title Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer.
title_full Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer.
title_fullStr Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer.
title_full_unstemmed Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer.
title_short Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer.
title_sort subtype specific expression of melk is partly due to copy number alterations in breast cancer
url https://doi.org/10.1371/journal.pone.0268693
work_keys_str_mv AT ashleyahardeman subtypespecificexpressionofmelkispartlyduetocopynumberalterationsinbreastcancer
AT yoojanehan subtypespecificexpressionofmelkispartlyduetocopynumberalterationsinbreastcancer
AT tatyanaagrushko subtypespecificexpressionofmelkispartlyduetocopynumberalterationsinbreastcancer
AT jeffreymueller subtypespecificexpressionofmelkispartlyduetocopynumberalterationsinbreastcancer
AT mariajgomez subtypespecificexpressionofmelkispartlyduetocopynumberalterationsinbreastcancer
AT yonglanzheng subtypespecificexpressionofmelkispartlyduetocopynumberalterationsinbreastcancer
AT olufunmilayoiolopade subtypespecificexpressionofmelkispartlyduetocopynumberalterationsinbreastcancer